Literature DB >> 18230572

[Methionine dependency of cancer cells: a new therapeutic approach?].

Xavier Durando1, Emilie Thivat, Pierre Gimbergues, Eric Cellarier, Catherine Abrial, Mathilde Dib, Olivier Tacca, Philippe Chollet.   

Abstract

Metabolic abnormalities of tumor cells offer opportunities of therapeutic targeting. In contrast to normal cells, tumor cells have absolute requirement for methionine (Met), an essential amino acid. Many molecular mechanisms have been considered to explain Met dependency. Several approaches have been used To reduce Met in vivo. As the main Met source was food, synthetic Met free diet were widely used. Alternatively, Met restriction was archived by the use of Met analogs or enzymatic degradation by methioninase. In animal models, Met restriction permit to limit tumor growth and to reduce tumor volume. However, interruption of Met restriction induce the regrowth of tumor. Moreover Met restriction induce several cells modifications suggesting its use in association with conventional chemotherapy. Preclinical studies have shown synergistic effect of the association of Met restriction and different cytostatic agents. Currently, few clinical investigations have been realised to test this therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18230572     DOI: 10.1684/bdc.2008.0550

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  3 in total

Review 1.  Effects of ionizing radiation on DNA methylation: from experimental biology to clinical applications.

Authors:  Isabelle R Miousse; Kristy R Kutanzi; Igor Koturbash
Journal:  Int J Radiat Biol       Date:  2017-02-21       Impact factor: 2.694

Review 2.  Targeting Nutrient Dependency in Cancer Treatment.

Authors:  Kexin Fan; Zhan Liu; Min Gao; Kangsheng Tu; Qiuran Xu; Yilei Zhang
Journal:  Front Oncol       Date:  2022-02-01       Impact factor: 6.244

3.  Functional identification of APIP as human mtnB, a key enzyme in the methionine salvage pathway.

Authors:  Camille Mary; Paula Duek; Lisa Salleron; Petra Tienz; Dirk Bumann; Amos Bairoch; Lydie Lane
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.